Prescient Therapeutics Limited (ASX:PTX) disclosed its quarterly results and operating highlights for the quarter ended on 30 June 2020.
At the end of June quarter, the Company had cash reserves of A$7.4 million. The main costs for the quarter comprised of the ongoing R&D costs across all Prescient programs.
During the quarter, PTX made a significant advance towards its goal of building a leadership position in the emerging next-generation of personalized cancer therapy and CAR-T treatment.
Which stock gained the most attention in 2019? Find out in our exclusive report on the much talked about lithium stocks which gained the most investor attention amidst the volatile and high drama electric vehicle market.
Read about the shift in the Electric Vehicle market in 2020 and the consequent focus on Lithium in our report.
Get an insight into the lithium prices and the trends. The supply glut kept the lithium prices in check. The escalated bilateral trade dispute between the United States and China significantly impacted the lithium chemical prices.
Understand the performance of mining companies. The lithium mining companies managed to sail through the turbulent white gold market by limiting the production in correspondence with the demand from the offtake partners.